Show notes
Pharmacists and Advocacy for Patients in Pain
Friday, August 21, 2026
What happens when patients living with chronic pain, their advocates, and the pharmacists responsible for dispensing opioid medications view the same healthcare system from very different perspectives?
This special episode of This Week in Pharmacy brings together the Doctor Patient Forum’s founders, Claudia A. Merandi and Bev C. Schechtman, with pharmacist and nationally recognized pharmacy advocate Dr. Shane Jerominski, PharmD—better known as “The Accidental Pharmacist.”
The discussion follows a wave of social-media debate surrounding Claudia’s use of the term “Harmacists,” which prompted responses from hundreds of pharmacists who felt the label misrepresented their professional responsibilities and the legal restrictions under which they practice.
Rather than allow that controversy to deepen the divide, TWIRx created an opportunity for direct, respectful conversation. The purpose of this episode is to help pain-patient advocates better understand the limits pharmacists face when dispensing opioids—and to identify opportunities for pharmacists and patient organizations to advocate together for safe, compassionate and uninterrupted pain care.
Five Legal and Supply-Chain Realities Affecting Opioid Dispensing
- Pharmacists have a federal “corresponding responsibility.”
Under 21 CFR §1306.04, a controlled-substance prescription must be issued for a legitimate medical purpose. Pharmacists share legal responsibility with prescribers for determining whether a prescription is valid. Knowingly filling an illegitimate prescription may expose the pharmacist to federal penalties and professional discipline. Review the federal regulation.
- Schedule II prescriptions must satisfy strict requirements.
Federal law generally requires a valid written or compliant electronic prescription before a Schedule II opioid may be dispensed. Emergency oral prescriptions are permitted only under limited conditions and require prescriber follow-up documentation.
- Schedule II opioid prescriptions cannot be refilled.
Under federal law, every additional dispensing generally requires a new prescription. Partial fills are allowed only under specific circumstances, documentation requirements and time limits. Pharmacists cannot simply extend or refill opioid therapy when a patient or prescriber requests it.
- State laws add another layer of requirements.
Depending on the state, pharmacists may have to verify prescriber authority, review prescription-monitoring information, validate electronic or security-form requirements, confirm identification, document partial fills, or comply with state-specific dispensing limitations. For example, California requires controlled-substance prescriptions to meet defined security and validity standards. California Board of Pharmacy guidance.
- Wholesaler monitoring can restrict a pharmacy’s opioid supply.
DEA-registered distributors must identify and report suspicious controlled-substance orders under 21 CFR §1301.74. National wholesalers therefore operate monitoring programs that may delay, limit or suspend shipments based on ordering patterns, geography, drug mix and internal thresholds. These controls are imposed upstream and can leave a pharmacy unable to obtain medication—even when the pharmacist believes a prescription is clinically and legally appropriate. Review the federal distributor requirements.
These examples are not exhaustive. Pharmacists must navigate overlapping federal law, DEA requirements, state pharmacy and controlled-substance laws, prescription-monitoring systems, employer policies, payer rules, wholesaler restrictions and professional standards. Requirements also vary by state and by the circumstances surrounding an individual prescription.
The Central Question
How can pain-patient advocates and pharmacists move beyond blame and work together to address the policies, supply restrictions, staffing conditions and regulatory pressures that can interfere with appropriate care?
This conversation explores:
- Why patients may interpret a refusal or delay as judgment, discrimination or abandonment
- Why pharmacists cannot treat a valid prescriber signature as automatic authorization to dispense
- How PDMP and risk-scoring information can influence clinical decisions
- The effect of corporate policies and wholesaler ordering controls
- The difference between professional judgment and stigma
- The communication failures that damage trust between patients, prescribers and pharmacists
- How advocacy organizations and pharmacists can pursue policy reform together
- Why patients deserve clear explanations, respectful treatment and continuity-of-care planning
- How pharmacists can remain vigilant without losing empathy for people living with pain
About the Doctor Patient Forum
The Doctor Patient Forum, founded by Claudia A. Merandi and Bev C. Schechtman, combines healthcare education, research, digital influence and patient advocacy to address the consequences of opioid-reduction policies and barriers to individualized pain care.
Claudia A. Merandi is an advocate and educator whose work contributed to a Rhode Island law protecting access to pain management. Since 2016, she has built a growing national audience while documenting systemic harms experienced by patients and healthcare professionals.
Bev C. Schechtman is a researcher, advocate and educator who examines opioid-reduction policies, prescription drug monitoring programs and surveillance technologies such as NarxCare. Her work helps patients understand and navigate an increasingly complex healthcare system.
Learn more: The Doctor Patient Forum
About Dr. Shane Jerominski, PharmD
Dr. Shane Jerominski is a pharmacist, Navy veteran and nationally recognized pharmacy advocate known as “The Accidental Pharmacist.” In 2025, his professional peers selected him as one of the “50 Most Influential People in Pharmacy.”
Through his influential social-media platform, Shane combines humor, candid commentary and frontline experience to advocate for safer working conditions, professional unity and meaningful reform throughout pharmacy practice. He is also a co-founder of The Pharmacy Guild and has become a prominent voice for pharmacists and pharmacy technicians nationwide.
A Call for Collaborative Advocacy
Patients should not be stigmatized because they require pain treatment. Pharmacists should not be vilified for complying with laws and professional obligations that can place their licenses and livelihoods at risk.
Progress requires both communities to recognize that many barriers originate beyond the pharmacy counter. Patients, pharmacists, prescribers and advocacy organizations share an interest in policies that protect medication safety without denying appropriate, individualized care.
The goal is not to determine which group has suffered more. The goal is to replace mistrust with understanding—and turn that understanding into stronger, unified advocacy.
This episode is intended for education and discussion. It does not provide legal or medical advice, and regulatory requirements may differ by jurisdiction and circumstance.
Our TOPPODCAST Picks 
Stay Connected
